Computational Biology and Chemogenomics Group

Dr Gary Newton's group develops computational tools to help cancer drug discovery efforts process the large amounts of data obtained through biomedical research.

Research, projects and publications in this group

Our group develops computational tools to promote cancer drug discovery via the processing of large amounts of data obtained through biomedical research.

Dr Gary Newton

Group Leader:

Medicinal Chemistry 3, Computational Biology and Chemogenomics Headshot of Gary Newton

Dr Gary Newton is a member of the Centre for Cancer Drug Discovery where he applies his medicinal chemistry experience to validate new targets and develop effective medicines for the treatment of cancer. He has worked in biotech and contract research organisations over the course of 20 years, leading groups to discover a number of pre-clinical candidates.

See profile

Researchers in this group

.

Email: [email protected]

See profile

.

Phone: +44 20 3437 6390

Email: [email protected]

Location: Sutton

See profile

.

Email: [email protected]

Location: Sutton

See profile

.

Email: [email protected]

See profile

.

Email: [email protected]

See profile

.

Phone: +44 20 3437 7515

Email: [email protected]

Location: Sutton

See profile

.

Email: [email protected]

See profile

.

Phone: +44 20 3437 6400

Email: [email protected]

Location: Sutton

See profile

Dr Gary Newton's group have written 21 publications

Most recent new publication 8/2023

See all their publications

Industrial partnership opportunities with this group

Opportunity: Discovering and developing small molecule inhibitors of ERAP1

Commissioner: Dr Esther Arwert

More details & apply...

Recent discoveries from this group

Shoulder-up profile image of Professor Paul Workman in a black suit and black shirt
Drug discovery researcher Professor Paul Workman awarded prestigious AAAS Fellowship

31/01/23

Professor Paul Workman, former Chief Executive and President of The Institute of Cancer Research, London, from 2014 to 2021, has been elected as a Fellow of the American Association for the Advancement of Science (AAAS), one of the most distinguished honours in the scientific community.
See full story
Cartoon representation of AKT2 kinase domain
AKT inhibitors: a new type of targeted cancer drug

12/05/22

To mark our outstanding success in REF2021, Alison Halliday shares the story of how our researchers revealed the 3D structure of the key cancer protein AKT, catalysing the discovery and development of at least 12 drugs now in clinical trials for a variety of cancers.
See full story
ICR Logo
canSAR: The AI ‘knowledgebase’ revolutionising cancer drug discovery

02/07/21

Since its release in 2011, canSAR has become the largest, public, cancer drug discovery resource in the world. On the 10-year anniversary of canSAR we take a look at how it’s shaping the future of drug discovery.
See full story
Assortment of multicoloured pills in a pile
Study polypharmacology earlier in drug discovery, say researchers

01/06/21

Polypharmacology – the ability of a drug to affect more than one protein – should be studied early in the drug discovery pathway, and constantly monitored as the chemical structure is optimised in the design of the clinical candidate, leading researchers believe.
See full story